Table 1 The association of deficient HLA class I expression in carcinoma with its progression in patients

Bladder

W6/32 and GRH1

The altered of HLA class I including total losses associates with higher grade lesions and tumor recurrence

[20]

A-072

1) 16.6% in G1, 38.5% in G2, and 57.1% in G3;

2) 5-year survival: 74% with positive versus 36% with negative staining

[21]

Gastric

A-072

0% in T1 (mucosa & submucosa) versus100% in T2-3 (muscle and fat invasion)

[22]

Esophageal

W6/32

0%: normal and benign versus 40.5% carcinoma lesions

[23]

Bronchogenic

W6/32 and HC-10

1) 13% of Diploid versus 45% of Aneuploid;

2) 17.3% in G1-2 versus 69% in G3

[24]

NSCLC

W6/32

1) 26.8% in T1-2 versus 35% in T3;

2) 20.7% in G1-2 versus 39.3% in G3; 3) 24.1% in N0 versus 34.5% in N1-2

[25]

Breast

HC-10

0% in low-grade versus 67.6% in high-grade lesions

[26]

W6/32

24% in primary versus 64% in corresponding LN samples

[27]

Pancreatic

W6/32 and 246-E8.E7

1) 6% in primary versus 43% in metastastic tumors;

2) 0% in G1, 33% in G2 and 67% in G3

[28]

Prostate

A-072

1) 0% in Benign, 41% in primary and 66% in LN metastases;

2) 33% in low-grade versus 50% in high grade lesions

[29]